Skip to main content

Errata - English

PDF CSV May 14, 2022 through May 14, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Sort descending Description
POWDERED ASHWAGANDHA ROOT EXTRACT COMPOSITION/Content of Withanolides USP40–NF35 6804 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Add
Solution B: Acetonitrile, filtered and degassed
OIL- AND WATER-SOLUBLE VITAMINS CAPSULES STRENGTH USP40–NF35 7290 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 23 of Sample solution: Change
Dilute a volume of this solution
to:
Sample solution: Dilute a volume of the Sample stock… Read More
NEOTAME ADDITIONAL REQUIREMENTS/USP Reference Standards <11> First Supplement to USP40–NF35 8485 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Neotame Related Compound A RS: Change
N-[3,3-Dimethylbutyl)-L-α-aspartyl]-L-phenylalanine.
to:
N-[N-(3,3-Dimethylbutyl)-L-α-aspartyl]-L-phenylalanine.
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS Assay USP40–NF35 4710 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Change
Buffer solution, Mobile phase, Internal standard solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate.
to:
Buffer solution—Dissolve 15.4 g of ammonium… Read More
ONDANSETRON INJECTION USP Reference standards <11> USP40–NF35 5443 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Ondansetron Related Compound A RS: Change
3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one.
to:
3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride.
MONOBASIC POTASSIUM PHOSPHATE IMPURITIES/Arsenic, Method I <211> USP40–NF35 7847 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1: Change
3 µg/g
to:
NMT 3 µg/g
OIL- AND WATER-SOLUBLE VITAMINS TABLETS STRENGTH USP40–NF35 7318 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 16 of Sample solution: Change
Dilute a 10-mL volume of this solution
to:
Sample solution: Dilute a 10-mL volume of the Sample… Read More
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS OTHER COMPONENTS/Content of Potassium Revision Bulletin (Official April 01, 2017) Online 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Sample solution: Change
Transfer 3.0 mL of the clear filtrate, reserved from the Assay, to a 100-mL volumetric flask.
to:
Sample stock solution: Dilute the clear filtrate, reserved from the Assay, with water to obtain a solution containing about 160… Read More
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS Dissolution <711>/Test 2 USP40–NF35 4710 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1: Change
Buffer solution and Mobile phase—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate.
to:
Buffer solution and Mobile phase—Prepare as directed in the Assay.
AND
Line 1 of Chromatographic system:… Read More
ONDANSETRON ORAL SOLUTION USP Reference standards <11> USP40–NF35 5444 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Ondansetron Related Compound A RS: Change
3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one.
to:
3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride.
CANDESARTAN CILEXETIL TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Second Supplement to USP40–NF35 8730 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Candesartan Cilexetil Related Compound D RS: Change
1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl 3-{[2’-(2-ethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate.
to:
1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 3-({2’-(2-… Read More
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES STRENGTH USP40–NF35 7336 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 23 of Vitamin A, Method 1/Sample solution: Change
Dilute a volume of this solution
to:
Sample solution: Dilute a volume of the… Read More
MEBENDAZOLE IMPURITIES/Organic Impurities/Table 2 USP40–NF35 4968 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Change footnotes
dEthyl 5-benzoyl-1-methylbenzimidazol-2-ylcarbamate.
eMethyl 5-(4-toluoyl)-1-methylbenzimidazol-2-ylcarbamate.
to:
dEthyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate.
eMethyl 5-(4-toluoyl)-1H-benzimidazol-2-… Read More
ONDANSETRON TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP40–NF35 5445 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Ondansetron Related Compound A RS: Change
3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one.
to:
3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride.
FLUVOXAMINE MALEATE CHEMICAL INFORMATION Second Supplement to USP40–NF35 8797 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 4:Change
5-Methoxy-4’-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1)
to:
(E)-5-Methoxy-4’-(trifluoromethyl)valerophenone O-(2-aminoethyl)oxime, maleate (1:1)
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS STRENGTH USP40–NF35 7375 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 16 of Sample solution: Change
Dilute a 10-mL volume of this solution
to:
Sample solution: Dilute a 10-mL volume of the Sample… Read More
REAGENTS REAGENT SPECIFICATIONS/Bromelain/Activity Determination USP40–NF35 2339 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Buffer solution: Change
Add 150 mg of sodium chloride
to:
Add 150 g of sodium chloride
MEMANTINE HYDROCHLORIDE TABLETS PERFORMANCE TESTS/Dissolution <711>/Analysis USP40–NF35 5000 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 In the variable definition list: Change
CS = concentration of USP Memantine Hydrochloride RS in the Standard solution (µg/mL)
to:
CS = concentration of USP Memantine Hydrochloride RS in the Standard stock solution (mg/mL)
PERPHENAZINE IMPURITIES/Organic Impurities/Chromatographic system USP40–NF35 5649 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Column: Change
4.6-mm
to:
4.0-mm
FLUVOXAMINE MALEATE IMPURITIES/Organic Impurities/Table 1 Second Supplement to USP40–NF35 8797 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Footnote b:Change
5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (E)-O-[2-[(2-succinyl)amino]ethyl]oxime.
to:
(E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-[2-[(2-succinyl)amino]ethyl]oxime.
AND
Footnotes c– g: Delete the space before… Read More
SHELLAC IMPURITIES/Limit of Chloride USP40–NF35 7869 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Control solution: Change
0.1 M hydrochloric acid VS,
to:
0.01 M hydrochloric acid VS,
REAGENTS, INDICATORS AND SOLUTIONS SOLUTIONS/Volumetric Solutions/1 N Sulfuric Acid VS USP40–NF35 2434 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 3 of Standardization: Change
dried at 150°
to:
dried at 105°
MYCOPHENOLATE MOFETIL FOR INJECTION ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP40–NF35 5250 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one.
to:
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H… Read More
PROPANTHELINE BROMIDE IMPURITIES/Organic Impurities/Chromatographic system USP40–NF35 5882 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Run time: Change
NMT
to:
NLT
EFAVIRENZ SPECIFIC TESTS/Enantiomeric Purity Second Supplement to USP40–NF35 Online 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Mobile phase: Change
Hexane and ethanol (97:3)
to:
Hexane and absolute alcohol (97:3)
<210> MONOSACCHARIDE ANALYSIS PROCEDURES/Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids First Supplement to USP40–NF35 8059 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 6 of Analysis: Change
(1 M = 1nmol/mL).
to:
(1 µM = 1nmol/mL).
CALCIPOTRIENE OINTMENT IMPURITIES/Organic Impurities USP40–NF35 3114 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Footnote a of Table 1: Change
(5Z,7Z,22E,24R)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol.
to:
(5Z,7Z,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol.
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP40–NF35 5251 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one.
to:
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H… Read More
ROCURONIUM BROMIDE IMPURITIES/Limit of 2-Propanol/Analysis USP40–NF35 6066 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of the variable definition list: Change
rU = peak response of any impurity from the Sample solution
rS = peak response of rocuronium bromide from the Dilute standard solution
to:
rU = peak… Read More
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS ASSAY/Procedure Revision Bulletin (Official April 01, 2017) Online 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Chromatographic system/Column: Change
10-µm
to:
5-µm
AND
In the variable definition list in Analysis: Change
rU = citrate peak area from the Sample solution
rS = citrate peak area from… Read More
G49 CHROMATOGRAPHIC COLUMNS/Packings First Supplement to USP40–NF35 8127 20-Apr-2019 USP42–NF37 First Supplement to USP41–NF36 Add
G49—Dimethylpolysiloxane with chiral building block containing D- or L-valine as chiral agent (for amino acids).
ENALAPRIL MALEATE TABLETS PERFORMANCE TESTS/Dissolution <711>/Table 1 USP40–NF35 3971 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Row 3 of Column 3: Change
100
to:
200
MYCOPHENOLATE SODIUM ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP40–NF35 5256 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one.
to:
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H… Read More
OIL-SOLUBLE VITAMINS CAPSULES STRENGTH USP40–NF35 7248 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 23 of Sample solution: Change
Dilute a volume of this solution
to:
Sample solution: Dilute a volume of the Sample stock… Read More
ACETAMINOPHEN AND CODEINE PHOSPHATE CAPSULES PERFORMANCE TESTS First Supplement to USP40–NF35 8201 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Dissolution <711>/Analysis:Change
Determine the labeled amount of acetaminophen
to:
Determine the percentage of the labeled amount of acetaminophen
AND
In the Calculate statement of Uniformity of Dosage Units <905>/Procedure for content… Read More
ENOXAPARIN SODIUM INJECTION SPECIFIC TESTS/Anti-Factor IIa Activity USP40–NF35 3982 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Delete
Standard solutions: Dilute USP Enoxaparin Sodium Solution for Bioassays RS with pH 7.4 buffer to obtain four dilutions having concentrations in the range between 0.015 and 0.075 IU of Anti-Factor IIa activity/mL.
MYCOPHENOLATE SODIUM IMPURITIES/Organic Impurities USP40–NF35 5256 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Footnote a of Table 2: Change
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one.
to:
(RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuran-1-one.
OIL-SOLUBLE VITAMINS TABLETS STRENGTH USP40–NF35 7258 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 16 of Sample solution: Change
Dilute a 10-mL volume of this solution
to:
Sample solution: Dilute a 10-mL volume of the Sample… Read More
ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS PERFORMANCE TESTS First Supplement to USP40–NF35 8202 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Dissolution <711>/Analysis:Change
Determine the labeled amount of acetaminophen
to:
Determine the percentage of the labeled amount of acetaminophen
AND
In the second Calculate statement in Uniformity of Dosage Units <905>/Procedure for… Read More
FENOLDOPAM MESYLATE USP Reference standards <11> USP40–NF35 4159 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Fenoldopam Related Compound A RS: Change
1-Methyl-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt).
C17H18ClNO3 · CH4SO3 415.89
to:
6-Chloro-1-(4-hydroxyphenyl)-3-… Read More
<581> VITAMIN D ASSAY ASSAY/Chromatographic Methods/Procedure 8 USP40–NF35 462 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Clean-up chromatographic system: Add
Flow rate: 1.1 mL/min
AND
Analytical chromatographic system: Add
Flow rate: 1.0 mL/min
PEMETREXED DISODIUM IMPURITIES/Organic Impurities/Table 2 USP40–NF35 5588 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Footnote b: Change
{4-[2-(2-Amino-1-methyl-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-L-glutamyl-L-glutamic acid.
to:
{4‐[2‐(2‐Amino‐4‐oxo‐4,7‐dihydro‐1H‐pyrrolo[2,3‐d]pyrimidin‐5‐yl)ethyl]benzoyl}‐4‐L‐glutamyl‐L‐glutamic acid.
OIL-SOLUBLE VITAMINS WITH MINERALS CAPSULES STRENGTH USP40–NF35 7265 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 21 of Sample solution: Change
Further dilute this solution
to:
Sample solution: Dilute the Sample stock solution
AND
Line 2… Read More
ERYTHROMYCIN OPHTHALMIC OINTMENT ASSAY/Procedure/Analysis First Supplement to USP40–NF35 8276 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 9 of the third variable definition list: Change
P = potency of erythromycin C in USP Erythromycin B RS (mg/mg)
to:
P = potency of erythromycin C in USP Erythromycin C RS (mg/mg)
GADOTERIDOL Chromatographic purity/Test 2 (Nongadolinium-Containing Impurities) USP40–NF35 4360 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of pH 5.0 Buffer: Change
50 mM Ammonium
to:
50 mM Ammonium phosphate buffer
AND
Line 1 of pH 7.0 Buffer: Change
50 mM Ammonium
to:
50 mM Ammonium phosphate buffer
DOXAZOSIN MESYLATE ASSAY/Procedure/System suitability/Suitability requirements USP40–NF35 3874 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Resolution: Change
NLT 4
to:
NLT 2
PEMETREXED FOR INJECTION ASSAY/Procedure/Analysis USP40–NF35 5590 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 In the variable definition list: Change
Mr2 = molecular weight of pemetrexed disodium, 597.49
to:
Mr2 = molecular weight of pemetrexed disodium (anhydrous), 473.37
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS STRENGTH USP40–NF35 7280 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 1 of Vitamin A/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 15 of Sample solution: Change
Further dilute this solution
to:
Sample solution: Dilute the Sample stock solution
AND
Line 2… Read More
LEVOTHYROXINE SODIUM TABLETS IMPURITIES/Limit of Liothyronine Sodium First Supplement to USP40–NF35 8328 1-Aug-2017 USP42–NF37 First Supplement to USP41–NF36 Line 4 of Analysis: Change
Calculate the percentage of levothyroxine sodium (C15H11I3NNaO4)
to:
Calculate the percentage of liothyronine sodium (C15H11I3NNaO4)
ISOSORBIDE DINITRATE EXTENDED-RELEASE CAPSULES Assay USP40–NF35 4708 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Change
Buffer solution, Mobile phase, Internal standard solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate.
to:
Buffer solution—Dissolve 15.4 g of ammonium… Read More